Price
$215.77-13.33%Social Signal Score
Analyst Ratings
27 analystsRevenue
$218.38MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Herriot Tabuteau
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,346
- Beta
- 0.60
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 6.22
Financials
Revenue
$218.38M+2375.9%Net Income
$-51.31MEBITDA
$-49.65MFree Cash Flow
$-32.83MEPS (diluted)
$-0.99Shares Outstanding (diluted)
51.50M+168.9%Operating Expenses
$254.36MCash & Debt
$319.85MRevenue by Segment (annual)
$633.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $638.50M | $-183.17M | $-3.68 |
| 2024 | $385.69M | $-287.22M | $-5.99 |
| 2023 | $270.60M | $-239.24M | $-5.27 |
| 2022 | $50.04M | $-187.13M | $-4.60 |
| 2021 | $0.00 | $-130.40M | $-3.47 |
| 2020 | $0.00 | $-102.90M | $-2.83 |
| 2019 | $0.00 | $-68.35M | $-2.05 |
| 2018 | $0.00 | $-30.97M | $-1.15 |
| 2017 | $0.00 | $-28.94M | $-1.27 |
| 2016 | $0.00 | $-27.20M | $-1.42 |
| 2015 | $0.00 | $-12.21M | $-0.88 |
| 2014 | $0.00 | $-6.00M | $-0.47 |
| 2013 | $0.00 | $-2.17M | $-0.28 |
Valuation
AXSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-67.74%Social Signal Score
Mentions (30)
- Newsglobenewswire.com·15d ago·Neutral
…ns, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheim…
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.
View source ↗ - News (RSS)fool·17d ago·Neutral
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
View source ↗ - Newsfool.com·17d ago·Positive
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.
View source ↗ - News (RSS)fool·17d ago·Negative
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
View source ↗ - Newsfool.com·18d ago·Negative
Is Axsome Therapeutics a Buy on the Dip? Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player's late-stage pipeline could translate into additional products over the next few years.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, bei…
View source ↗ - Newsseekingalpha.com·19d ago·Neutral
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·24d ago·Positive
Axsome rises on Auvelity prescription data
View source ↗ - News (RSS)seekingalpha·25d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·25d ago·Negative
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Neutral
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
Axsome Therapeutics (AXSM) Gains Buy Rating Amid Smoking Cessation Trial, But Valuation Remains Elevated Wainwright reaffirmed its Buy rating on [+276 characters]
View source ↗ - News (RSS)investing·35d ago·Neutral
Axsome doses first patient in phase 3 smoking cessation trial
View source ↗ - News (RSS)yahoo·37d ago·Positive
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
View source ↗ - News (Marketaux)finance.yahoo.com·43d ago·Positive
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run Axsome Therapeutics (<[+293 characters]
View source ↗ - News (RSS)fool·43d ago·Neutral
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run The company has also crushed broader equities over the past five years.
View source ↗ - Newsfool.com·43d ago·Neutral
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company's deep pipeline may help it launch newer products and post consistent revenue growth for a while.
View source ↗ - Newszacks.com·55d ago·Negative
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt
View source ↗ - News (Marketaux)seekingalpha.com·56d ago·Neutral
Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11 Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·56d ago·Neutral
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·57d ago·Negative
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
View source ↗ - Newsmarketbeat.com·57d ago·Positive
Axsome Therapeutics Q2 Earnings Call Highlights Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-0.51 per share
Typical surprise -11.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.99 vs $-0.89miss
- Mon, May 4$-1.26 vs $-0.85miss
- Mon, Feb 23$-0.71 vs $-0.70miss
- Mon, Nov 3$-0.94 vs $-0.82miss
- Mon, Aug 4$-0.92 vs $-1.00beat
- Mon, May 5$-1.22 vs $-1.26beat
Estimates and results for AXSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AXSM officers and directors.
- Bought
- —
- Sold
- $111.5m
0 trades
29 trades
- Jacobson Mark L.sold
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·4,660 @ $213.95·$997k·Aug 6, 2026·filing
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·45,004 @ $212.01·$9.5m·Aug 5, 2026·filing
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·49,666 @ $240.25·$11.9m·Jul 1, 2026·filing
- Jeffs Rogersold
- Jeffs Rogersold
- Mahony Susansold
- Coleman Marksold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AXSM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.